SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain ...

"Today is one of the most important strategic milestones in the history of our company," commented Joe Burnett, President and CEO at ClearPoint Neuro. "FDA's granting of this De Novo ...

Carson Schwesinger continues to be on a tear this year and is starting to receive recognition as one of the nation's best linebackers. In UCLA's Homecoming win over Iowa on Friday, the redshirt ...

Daily Bruin reporter Matthew Niiya breaks down UCLA men’s basketball’s roster as play opens up for the 2024-2025 campaign. Andrews elevates for a 3-pointer. (Aidan Sun/Assistant Photo editor ...

Touted a leader on the Bruin roster this season, Stefanovic has been far from one to expatiate on his reduced minutes – the Serbian senior has embraced whatever Cronin has handed him and warmly ...

Benzinga Neuro, our in-house GPT-4-based content generation system, exploits the extensive Benzinga Ecosystem, including native data, APIs and more to create comprehensive and timely stories for you.

Sellers have always spent a great deal of time, money and energy trying to find ways to influence buyers' decisions. Now, thanks in part to the increasing accessibility of functional magnetic ...

86,482 people died in Germany in October 2024, according to extrapolated figures of the Federal Statistical Office (Destatis). This corresponds roughly to the 2020 to 2023 median for that month (+2%).

Nov. 12, 2024 — A practical calculator predicts the risk of epilepsy after venous stroke. The aim is to improve care for those affected, which are predominantly young ... Researchers Identify a ...

Zo werd er veel gesproken over haar moed om zich zo kwetsbaar op te stellen voor de camera. Inge de Bruin in bikini op Bonaire Inge toont zich van haar sportiefste kant, en haar lichaam is het bewijs ...

“Today is one of the most important strategic milestones in the history of our company,” commented Joe Burnett, President and CEO at ClearPoint Neuro. “FDA’s granting of this De Novo classification is ...